TP53 and acute myeloid leukemia: Specifically, among 131 previously untreated AML patients, Morita et al. observed frequent persistence of somatic mutation at CR in genes that are often pre-leukemic and associated with clonal hematopoiesis of undetermined significance (CHIP), namely DNMT3A, TET2, SRSF2, ASXL1 and TP53, whereas mutations in NPM1 gene, transcription factors or receptor tyrosine kinase genes were often cleared [109].